Single- and multiple-dose pharmacokinetics of pioglitazone in adolescents with type 2 diabetes.

@article{Christensen2005SingleAM,
  title={Single- and multiple-dose pharmacokinetics of pioglitazone in adolescents with type 2 diabetes.},
  author={Michael L. Christensen and Bernd Meibohm and Edmund Capparelli and Pedro A Vel{\'a}squez-Mieyer and George A. Burghen and William V Tamborlane},
  journal={Journal of clinical pharmacology},
  year={2005},
  volume={45 10},
  pages={1137-44}
}
This study assessed the single- and multiple-dose pharmacokinetics of 3 doses (15 mg, 30 mg, and 45 mg) of pioglitazone in 36 adolescents with type 2 diabetes. Blood samples were obtained over a 48-hour interval after the first dose (day 1) and over a 72-hour interval after the last dose (day 15) of pioglitazone and were assayed for pioglitazone and active metabolites (M-III and M-IV). Pioglitazone systemic exposure increased dose dependently but was less than dose proportional during multiple… CONTINUE READING